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Abstract: The obstructive sleep apnea syndrome (OSAS) represents only part of a large group of
pathologies of variable entity called respiratory sleep disorders (RSD) which include simple snoring
and increased upper airway resistance syndrome (UARS). Although the etiopathogenesis of adult
OSAS is well known, many aspects of this syndrome in children are still debated. Its prevalence
is about 2% in children from 2 to 8 years of age, mostly related to the size of the upper airways
adenoid tissue. Several risk factors linked to the development of OSAS are typical of the pediatric
age. The object of this paper is to analyze the state of the art on this specific topic, discussing its
implications in terms of diagnosis and management.
Keywords: pediatric OSAS; obesity; adenotonsillar hypertrophy; craniofacial abnormalities; allergic
rhinitis; inflammation
1. Introduction
Respiratory sleep disorders (RSD) in children are characterized by a variable obstruction of the
upper airway and different degrees of alteration in gas exchange during the night [1,2].
The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSAS as a
polysomnography (PSG)-determined obstructive respiratory disturbance index (RDI) ≥ 5 events/h
associated with the typical symptoms of OSAS (e.g., unrefreshing sleep, daytime sleepiness, fatigue
or insomnia, awakening with a gasping or choking sensation, loud snoring, or witnessed apneas),
or an obstructive RDI ≥ 15 events/h (even in the absence of symptoms) [3]. In addition to the apneas
and hypopneas that are included in the Apnea-Hypopnea Index (AHI), the RDI includes respiratory
effort-related arousals (RERAs). The scoring of respiratory events is defined in the AASM Manual for
the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version
2.3 (AASM Scoring Manual) [4]. However, some variability in the definition of a hypopnea event
should be noted.
According to the AASM Scoring Manual recommended definition, changes in flow should be
associated with a 3% oxygen desaturation or a cortical arousal, although an alternative definition
that requires association with a 4% oxygen desaturation without consideration of cortical arousals is
accepted. Depending on which definition is used, the AHI may be considerably different in any given
Int. J. Environ. Res. Public Health 2019, 16, 3235; doi:10.3390/ijerph16183235 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2019, 16, 3235 2 of 20
individual [5–7]. The discrepancy between these and other hypopnea definitions used in research
studies makes the evaluation of evidence regarding the diagnosis of OSAS a complex matter.
The apnea-hypopnea index (AHI) is the average number of disordered breathing events per hour.
Typically, the OSA syndrome is defined as an AHI of 5 or greater. An AHI of 5–15 is considered as
mild, 15–30 is moderate and more than 30 events per hour characterizes severe sleep apnea.
The precise incidence of OSAS in adults is still unknown. It is estimated that 24 percent of men
and 9 percent of women have the breathing symptoms of OSAS with or without daytime sleepiness,
but about 80 percent of adults with OSAS remain undiagnosed [8].
On the other hand, respiratory sleep disorders (RSD) in children are characterized by a variable
obstruction of the upper airway and different degrees of alteration in gas exchange during the night.
The clinical presentation goes from habitual snoring to complete obstruction of the airway [9,10].
The European Respiratory Society (ERS) taskforce for the diagnosis and management of obstructive RSD
in childhood defines OSAS as “a syndrome of upper airway dysfunction during sleep, characterized
by snoring and/or increased respiratory effort secondary to increased upper airway resistance and
pharyngeal collapsibility” [11]. In childhood OSAS there is not a clear correlation between the severity
of the clinical presentation and daytime symptoms, with a more nuanced range of symptoms [12].
Gozal et al. [13] proposed several criteria, classified into major and minor, for the diagnosis
of OSAS in children and, above all, to assess the need for treatment. The major ones include an
AHI > 2, RDI > 2, Nadir SpO2 < 90%, excessive daytime sleepiness, academic difficulties, hyperactive
behavior, hypertension, enuresis, and obesity. Among the minor ones, there are high levels of CRP,
LDL, fasting insulin and low levels of HDL, recurrent middle ear otitis and adenotonsillar grade >1.
The positivity of five major criteria, or three major criteria plus 3 minor criteria, indicates the need for
therapeutic procedures.
According to latest guidelines, the general incidence of OSAS in the pediatric population is about
2% [9]. Most children are around 2–8 years of age, due to the relative size of the lymphatic tissue
of the upper airways [14]. OSAS is more common in males than females. African Americans and
obese children are both at increased risk for OSAS [15]. While many studies have addressed the
etiopathogenesis of adult OSAS, many aspects of this syndrome in children remain unclear. However,
there are many risk factors which can lead to a reduction or collapse of the upper airways and which
may contribute to the pathogenesis of OSAS.
The diagnosis of pediatric OSAS include a detailed clinical history, focusing on physical findings,
especially in the ENT district, nocturnal and diurnal symptoms and comorbidities followed by specific
questionnaires administered to parents. Nocturnal oximetry and ambulatory polysomnography are
mandatory. In patients with residual OSAS after surgery, DISE should be considered to detect the
anatomical site of potential collapse.
To our knowledge, few papers have been published on the risk factors linked to OSAS, especially
in the pediatric age [9,16]. We were able to find out 182 articles from 2012 to 2019 on Pubmed and
MEDLINE using the keywords “Risk factors; Pediatric OSAS; Obesity; Adenotonsillar hypertrophy;
Craniofacial abnormalities; Allergic rhinitis; Inflammation”. Only 123 articles discussed this specific
topic in children. Furthermore, it should be noted that the majority of the papers analyzed only one
single risk factor and rarely multiple factors, focusing essentially on the overview of the OSAS. The very
exhaustive papers published by Marcus C.L. et al. [9] and Li Z. et al. [16] are typical examples of this
observation. They made a general, wonderful presentation of the pathology, but dedicated just a few
paragraphs in evaluating the various risk factors.
Thus, the aim of this paper is devoted to analyzing the state of the art on this specific and its
impact on diagnosis and treatment.
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2. Risk Factors
2.1. Obesity
Obesity is one of the most important risk factors for OSAS in both the adult and pediatric
populations.
Obesity affects OSAS mainly through two mechanisms: The presence of fat at the level of the
pharyngeal soft tissue reduces the caliber of the lumen and increases the collapse of the structures
themselves. Secondly, the increased presence of fat in the thoracic and abdominal walls significantly
reduces respiratory function in these patients [17,18].
Each increment in body mass index (BMI) above the 50th percentile is associated with around a
10% increased risk for OSAS [19].
From 1975 to 2016, the mean BMI in children and adolescents increased globally, up to 18.6 kg/m2
(18.4–18.7) for girls and 18.5 kg/m2 (18.3–18.7) for boys in 2016. Moreover, childhood obesity is not
only a widespread phenomenon, but also a persistent one: About 50% of obese children are also likely
to be obese adults [20].
Overweight or obese children have a higher risk of developing OSAS compared with normal-
weighted children [21].
Even though adenotonsillectomy (AT) represents the first line therapy for these children, several
studies have reported that obesity increases the risk of persistent OSAS after surgery [22–25]. To this
regard Xu Z. et al. reported a direct correlation between the body mass index standard deviation score
(BMI SDS) and the apnea-hypopnea index (AHI) [26].
Weight-loss management could be the key in the treatment of obesity-related OSAS in children and
adolescents; specially in those that have previously performed adeno-tonsillectomy surgery without
clinical results. Despite many studies supported weight-loss management as a key point therapy for
OSAS in obese adults, only a few have studied the effect of obesity treatment on childhood OSA [27–29].
Andersen I.G. et al. [30] conducted a prospective longitudinal study on a population of 62 children and
adolescents treated in a chronic care multidisciplinary overweight- and obesity treatment clinic. They
observed a normalization of AHI in 38% of them after 6 months of obesity treatment and in 44% after
one year of weight-loss.
These evidence lead us to consider weight-loss as first line therapy for these children with
elevated BMI.
Studies that have analyzed obesity as pediatric OSAS risk factor are reported in Table 1.
Table 1. Studies that have analyzed obesity as a pediatric OSA risk factor.
Study Year Type of Study PatientsNumber Age
Parameters
Evaluated Conclusions
Arens R et al.
[18] 2018
Case-control
study 44 12.5 ± 2.8
Anatomical findings
in obese children
affected by OSAS
compared to the ones
in obese children
Significant upper airway
lymphoid hypertrophy in
obese children with OSAS.
Larger parapharyngeal fat
in obese children with
OSAS but not a direct
association with severity of
OSAS or with obesity
Su M. et al.
[21] 2016
Epidemiological
study 5930 3–11
Age and sex;
No positive correlation
between OSA and BMI
AHI;
Arousal index;
BMI;
Mallampati;
AT hypertrophy;
Nocturnal/daytime
symptoms
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Table 1. Cont.
Study Year Type of Study PatientsNumber Age
Parameters
Evaluated Conclusions
Xu Z. et al.
[26] 2008
Case-control
Study 198 10.3 ± 2.1
Age and sex;
Positive relation between
OSAS and degree of obesity
BMI;
Waist circumference;
Neck circumference;
Waist-to-Height Ratio;
Symptoms;
AHI, Obstructive
Apnea Index, Central
Apnea, MinSaO2;
AT hypertrophy
Andersen
I.G. et al.
[30]
2019
Longitudinal
study 62 13.4 ± 3.1
Age and sex;
AHI normalization in 44%
of patients and positive
correlation between BMI
and AHI parameters
BMI;
AT hypertrophy;
AHI;
Sleep time (hours);
ODI
2.2. Adenoid and/or Tonsil Hypertrophy
The lymphoid tissue of the Waldeyer ring is more developed at an age between 3 and 6 years,
according to the peak incidence of OSAS [31,32]. Adenoid and/or tonsil hypertrophy are the most
common causes of upper airway lumen reduction in children, evaluated by the Friedman Grading
Scale (Table 2).
Table 2. Reproducibility of clinical grading of tonsillar size.
Grade Description
0 No tonsils seen
I In tonsillar fossa
II Visible beyond anterior pillars
III Extended 34 of way to midline
IV Completely obstructing airway (kissing tonsils)
Adenotonsillar hypetrophy contributes to the narrowing of the retro-palatal area, which has
the smallest cross-sectional area and is therefore the most frequent site of obstruction, as shown in a
6 years old patient in Figure 1. In particular, children with Grade IV tonsils (kissing tonsils) are very
susceptible to developing sleep disorders, due to oropharyngeal narrowing and lateral collapse.
Adenotonsillar hypertrophy leads to mouth breathing, nasal congestion, hyponasal speech,
snoring, chronic sinusitis, and recurrent otitis media, as well as poor brain development and emotional
disturbances. Kurnatowski P. et al. [33] in their study of six- to nine-year-old children reported high
scores of emotional instability in the adenotonsillar hypertrophy group, compared to healthy controls,
with good results on the behavior of most of the children 3–10 months after surgery. Some authors
highlighted the role of inflammation in the development of adenotonsillar hypertrophy and OSAS,
given the increased expression of various mediators of inflammatory responses in the tonsils and
improvement following treatment with anti-inflammatory agents such as corticosteroids, suggesting a
multi-disciplinary approach for treatment.
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Fig re 1. Grade III tonsil hypertrophy in a 6 year-old child. Courtesy of Professor C. Vicini—Department
of Head-Neck Surgery, Otolaryngology, Head-Neck and Oral Surgery Unit, Morgagni Pieranto i
Hospital, Forlì, Italy.
The g ld standard of surgical treatmen is represented by adenotonsillectomy [9,34]. Brietzke et al. [34]
demonstrated the resolu on of the polysomnographic findings in 83% of childre with OSAS without
other co-morbidities. Several recent studies h ve confirmed the efficacy but have suggested long-term
foll w up, especially in children with concomita t comorbiditie , in order to avoid residual OSAS [35,36].
On t e other hand, in the adult OSAS population, t nsillect my is more often ass ciated with palatal
surg ry. However, Senchak AJ et al. [37] proposed tonsill ctomy as is l ted surgery. T ey en lled
202 subjects. The AHI b fore surgery ranged f om 5.4 to 56.4 eve ts per h ur. The m an AHI
decreased from 18 to 3.2 events per hour, a reduction of 82%. Following tonsillectomy alone, there
were statistically significant reductions in median RDI and in the Epworth Sleepiness Scale (ESS) and
Berlin scores. They drew the conclusion that adult tonsillectomy alone could be effective, especially in
young overweight men with large tonsils, moderate OSAS and low Friedman stage.
Recent studies have also suggested the role of lingual tonsil hypertrophy in the pathogenesis
of pediatric OSAS, as frequent evidenced in the adult population [8–12]. Figure 2 shows lingual
hypertrophy in a 11-year-old child. In adults, the procedure of reducing lingual tonsil through Trans
Oral Robotic Surgery (TORS) is widely used. In children, it is not a common procedure [38,39].
In particular, the young patient of Figure 3 underwent robotic surgery due to severe OSAS with
disabling symptoms without adenotonsillar hypertrophy or other risk factors.
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Figure 3. Transoral robotic surgery (TORS) to remove an exuberant lingual tonsil in a 12-year-old child.
Courtesy of Professor C. Vicini—Department of Head-Neck Surgery, Otolaryngology, Head-Neck and
Oral Surgery Unit, Morgagni Pierantoni Hospital, Forlì, Italy.
The possibility of intracapsular tonsillotomy using Debrider or Coblation should be considered
in this type of surgery in order to remove only the exuberant lymphatic tissue of tonsils. Reported
similar intracapsular tonsillotomy seems to show similar results in terms of AHI reduction with respect
classical extracapsular tonsillectomy with a lower risk of postoperative bleeding [40].
Supraglottoplasty in cases of laryngomalacia associated with exuberant arytenoid tissue or
epiglottoplasty in case of epiglottis hypertrophy/instability, are possible treatment options and should
always be considered [37,38].
Midline posterior glossectomy is less frequently performed in pediatric OSAS patients [41].
Studies that have analyzed adenoid and/or tonsil hypertrophy as a pediatric OSAS risk factor
have been reported in Table 3.
Table 3. Studies that have analyzed adenoid and/or tonsil hypertrophy as a pediatric OSAS risk factor.
Study Year Type of Study Patientsn◦ Age Parameters Evaluated Conclusions
Kurnatowski
P. et al. [33] 2007
Case–control
study 225 10–13
Age and sex; Negative emotional
effect of adenotonsillar
hypertrophy
induced obstructive
sleep disordered
breathing
Total sleep time;
AHI, ODI;
AT grade sec. Friedman;
Spielberger test;
Capra and Pastorelli scale
Brietzke S.E.
et al. [34] 2006
Meta-analysis
(14 studies)
28
(mean)
4.9 (pooled
mean age)
Age; AT effective in reducing
severity of OSAS in
majority of patients
Pre AT AHI;
Post AT AHI;
Success of AT;
Kang K.T. et
al. [38] 2017
Meta-analysis
(4 studies)
18.25
(mean)
8.3 ± 1.1
(mean)
Age;
Effectiveness of lingual
tonsillectomy for
children with OSA
caused by lingual tonsil
hypertrophy
BMI;
Other comorbidities;
CT, RMN, DISE;
Preoperative AHI;
Postoperative AHI
Preoperative ODI;
Postoperative ODI
Lee C.F. et al.
[41] 2016
Meta-analysis
(11 studies)
11
(mean)
3.7 (mean)
Age;
Effectiveness in
reducing AHI and
MinSaO2, but complete
resolution not achieved
in most cases
BMI;
Preoperative AHI;
Postoperative AHI
Preoperative ODI;
Postoperative ODI
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2.3. Allergic Rhinitis
It is believed that allergic rhinitis (AR) can affect sleep through different mechanisms. Nasal
congestion secondary to the nasal mucosa inflammatory process induces increased airway resistance
and may result in oral breathing, sleep disruption, and fatigue [42].
Nasal patency is mainly regulated by the capacitance vessels of the middle and inferior
turbinates [43]. What happens in an allergic patient is an increased nasal resistance with dilatation
of these capacitance vessels, with mucosal edema and mucous secretions [44]. The most common
symptoms of allergic rhinitis patients are rhinorrhea, nasal blockage or congestion, and stuffy nose.
Clearly, nasal obstruction is also associated with olfactory disorders because of the reduction of
odourants that enter the nose during breathing [45,46].
Further exacerbating airflow limitation, an increase in airflow velocity may cause paradoxical
airway narrowing in the nasal valve and, as the obstruction progresses, in the oropharynx too.
Lofaso et al. [47] used posterior rhinomanometry to highlight the correlation between nasal
obstruction and OSAS severity, independently of other risk factors. They evaluated 541 unselected
consecutive snorers referred for suspected breathing disorders during sleep over a 2 year period.
In addition, cephalometric landmarks and body mass index (BMI) were obtained. Polysomnography
was used to determine the number of abnormal respiratory events that occurred during sleep. They
concluded that permanent physical nasal obstruction unresponsive to nasal decongestants, and
functional nasal obstruction responsive to nasal decongestants, such as those that occur during
vasomotor rhinitis, may contribute to sleep-disordered breathing. and is an independent risk factor
for OSAS.
McNicholas WT [48] et al. demonstrated longer and more frequent obstructive apneas in
patients with allergic rhinitis to ragweed, especially during the ragweed season rather than after the
pollen season [47]. Furthermore, an elevated Mallampati score seems to have a synergistic effect in
these patients.
Liistro et al. [49] proposed a two-hit phenomenon, with a higher relative risk for OSA in those with
a reduced posterior pharynx space due to tongue base hypertrophy and nasal obstruction, compared
to those with only one of these risk factors.
Additionally, inflammatory mediators of the allergic process, such as histamine and certain
cytokines, may act directly on the central nervous system by altering sleep rhythm. It has been recently
observed in children with sleep disorders, that the presence of allergic rhinitis (without obstructive
sleep apnea) decreases REM (Rapid Eye Movement) sleep time [50]. A recent meta-analysis from
Cao Y. et al. [51] evaluated the association between allergic rhinitis and obstructive sleep apnea in
both adult and pediatric population. They included 44 studies, comprising 6086 participants. They
reported an incidence of children diagnosed with AR 2.12 times higher in OSA/RSD patients. However,
the same trend was not found in the adult population. The possible cause is related to the immaturity
of the immune system in children. Medical treatment, such as nasal steroids and oral montelukast has
been studied as a treatment option for OSAS children with concomitant allergic rhinitis and asthma.
Kheirandish-Gozal et al. [52] described an overall success rate of 80% in children aged 2–14 years
using intranasal steroid therapy and oral montelukast. The same group recently compared the effect
of 16 weeks of oral montelukast therapy with placebo for treatment of childhood OSAS with good
results [53].
More recently, the American Academy of Pediatrics stated that nasal steroid therapy is indicated
for children with mild OSAS who cannot undergo surgery or for those with persisting residual OSAS
after surgery [54].
Studies that have analyzed allergic rhinitis as a pediatric OSA risk factor have been reported in
Table 4.
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Table 4. Studies that have analyzed allergic rhinitis as a pediatric OSA risk factor.
Study Year Type of Study Patientsn◦ Age Parameters Evaluated Conclusions
Cao Y. et al.
[51] 2018
Meta-analysis
(44 studies)
6086
total
patients
47.97
(adults)
7.73
(children)
Age and Sex; Children with OSA
suffering from a higher
incidence of AR. OSA
adults with AR do not
have any influences on
sleep parameters
BMI;
Neck circumference;
AHI;
ESS;
AR prevalence
Kheirandish-
Gozal L. et
al. [52]
2014 Retrospective
review
3071 2–14
Age and Sex;
Effective alternative to
adenotonsillectomy,
particularly in younger
and non-obese
Children
BMI;
Pretreatment: AT grade;
Mallampati;
Total sleep time;
AHI, ODI;
Posttreatment:
Pretreatment: AT grade;
Mallampati;
Total sleep time;
AHI, ODI
Kheirandish-
Gozal L. et
al. [53]
2016
Prospective
randomized
trial study
92 2–10
Age and Sex;
Beneficial effects
(reduction of AHI and
ODI) in 71% of children
treated with
montelukast. No
changes in those treated
with placebo.
BMI;
Pretreatment: AT grade;
Mallampati;
Total sleep time;
AHI, ODI;
Posttreatment:
Pretreatment: AT grade;
Mallampati;
Total sleep time;
AHI, ODI
Brouillette
R.T. et al.
[54]
2001
Triple-blind
randomized
placebo-controlled
trial
25 1–10
Age and Sex;
Decrease in AHI/ODI
values in 12/13 of
fluticasone group. No
changes in placebo
group
Pretreatment:
AHI, ODI;
Total sleep time;
AT grade;
AR symptoms
Posttreatment: AHI, ODI;
Total sleep time;
AT grade;
AR symptoms
2.4. Craniofacial Abnormalities and Genetics
Craniofacial abnormalities can also be a cause of upper airway obstruction syndrome. Alterations
of the size, position, and geometry of the mandible and of the tongue can lead to the thickening of
the retro-palatal region which, as already mentioned above, is the most frequent site of obstruction in
pediatric patients. [55,56].
The exact role of genetics in the pathogenesis of pediatric OSAS is still a matter of debate. What is
known is that some clinical syndromes such as Down, Prader–Willi and Beckwith–Wiedemann are
strongly associated with OSAS. Studies focus mostly on gene polymorphisms, for example, the ApoE4
allele, TNFa 308G gene polymorphism, NADPH polymorphism [57–60].
Zaffanello M. et al. [61] reported other genetic syndromes that could be cause of OSAS:
Achondroplasia [62–65], Ehlers–Danlos Syndrome [66,67], Pierre Robin sequence/complex [68],
Ellis–van Creveld Syndrome [69], sickle cell disease [70] and Noonan Syndrome [71]. Any congenital or
acquired conditions that involve the respiratory control center may potentially lead to the development
of OSAS. Myelomeningocele, Arnold Chiari malformation, and brain injuries from trauma, tumors,
surgery can be other causes of pediatric OSAS [72,73]. In such patients, surgical treatment often
represents the only option possible. Maxillo-mandibular advancement (MMA) is one of the most
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common type of surgical procedures performed in these cases. It provides an enlargement the
nasopharynx, oropharynx, and hypopharynx by advancing the soft palate and tongue and shrinking
the lateral pharyngeal walls.
Saxby et al. [74] evaluated maxillomandibular advancement surgery as the gold standard for
children affected by syndromic craniofacial abnormalities. The procedure showed an improvement of
the Apnea-Hypopnea Index score and OSA grading in most of their 65 patients, although measures of
oxygenation revealed no differences.
On the other hand, in the adult population, the indication for mid-face advancement should take
into account the complication rate and cosmetic sequelae. For this reason, it is not considered as a first
line option in children without facial abnormalities [75].
Orthodontic treatment represents a valid alternative in patients only presenting high-arched or
narrow palates, susceptible to OSAS. The use of rapid maxillary expansion, an appliance to widen
the palate and flatten the palatal arch, has shown very good polysomnographic outcomes in a recent
meta-analysis [76]. Villa et al. [77] proposed oral appliance therapy for children presenting moderate
to severe OSAS with malocclusion.
Studies that have analyzed craniofacial abnormalities and genetics as pediatric OSA risk factor
have been reported in Table 5.
Table 5. Studies that have analyzed craniofacial abnormalities and genetics as a pediatric OSA
risk factor.
Study Year Type of Study PatientsNumber Age Parameters Evaluated Conclusions
Follmar A.
et al. [58] 2014
Retrospective
cohort study 118
1 day–15
years
RDI;
Multifactorial etiology of
RSD in children affected by
Prader–Willi Syndrome
Laryngomalacia;
macroglossia,
AT hypertrophy;
GERD.
Onodera K.
et al. [62] 2005
Case–control
study 30
3.8 ± 1.4
(20) 7.9 ± 3
(10)
Questionnaire items:
Significant presence of RSD
in patients affected by
achondroplasia (AP)
Snoring;
AHI;
Mouth breathing;
Occlusion;
Height and weight;
Ages of the eruption of
deciduous teeth
Pavone M.
et al. [66]
2015
Retrospective
study 88 1–14.5
Anthropometric data; No correlations between
MOAHI and age or BMI,
positive correlations
between MOAHI and Sp02
BMI;
MOAHI, RDI, SpO2
Guilleminault
C. et al. [67]
2013
Retrospective
study
34
patients 26.55
Clinical evaluation;
Commonly unrecognized
abnormal breathing and its
correlation with daytime
fatigue and poor sleep in
Ehlers–Danlos patients
Rhinomanometry;
AHI, RDI, Sa02
Kalaskar R
et al. [69] 2012
Case report
study 1
11 years
old boy
Anatomical finding;
orthodontic
conformation
Association between
Ellis–van Creveld
syndrome and OSA
Cardiel Rios
S.A. et al.
[71]
2016 Case reportstudy 1
10 years
old boy
Anatomical finding;
orthodontic
conformation
Association between
Noonan syndrome,
malocclusion and OSA
Saxby C.
et al. [74] 2018
Retrospective
study 65
Not
specified
Patients demographics;
Type of midface
advancement;
Positive outcomes after
midface advancement in
patients with
craniosynostosis
Preoperative: AHI, RDI,
SaO2;
Postoperative: AHI,
RDI, SaO2;
Blood pressure;
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Table 5. Cont.
Study Year Type of Study PatientsNumber Age Parameters Evaluated Conclusions
Villa M.P.
et al. [77] 2002
Randomized
controlled
study
32 4–10
Brouillette
questionnaire;
Improved respiratory
symptoms in patients who
underwent oral appliance
treatments
physical examinations:
AHI, RDI, SaO2
2.5. Inflammatory Factors and Biomarkers
It is believed that inflammation and OSAS are strongly related. In fact, systemic inflammatory
markers level such as NF-κB, C-reactive protein (CRP), TNF-a, IL-6, IL-8 IL-1a, IL-1b, and IFN-g are
upregulated in subjects with OSAS. On the other hand, the concomitant reduction of anti-inflammatory
factor IL-10 suggests a tilted proinflammatory state in OSAS [78–80].
Several studies have highlighted the role of oxidative stress in the genesis of endothelial
damage in both adult and pediatric OSAS patients [81,82]. Intermittent hypoxemia leads to anoxia
and re-oxygenation, which triggers the production of oxygen radicals and consequently local and
systemic inflammation.
Many studies have suggested the involvement of the NF-κB-related inflammatory pathway in
the pathogenesis of OSAS. The upregulation of NF-κB increases the expression of pro-inflammatory
mediators and cytokines (TNF- α, IL-6, and CRP), resulting in blood vessel endothelial damage and
systemic inflammation. It is widely accepted that a correlation exists between systemic inflammation
and the progression of atherosclerosis and coronary artery disease in adults.
Although in adults the association between inflammation and OSA is well known, in children it
is still under debate. In children, inflammatory markers (local and systemic) and proinflammatory
cytokines are upregulated, which further advances lymphoid tissue proliferation. Many studies are
being conducted on the use of biomarkers for the diagnosis of OSAS, based on the high levels of
pro-inflammatory factors.
Biomarkers are non-invasive and simple tests to integrate diagnosis. Kallikrein-1, orosomucoid-1,
uromodulin and urocotin-3 are those most frequently used. In fact, their relevance lies on the diagnostic
precision in finding children affected by OSAS [83,84]. Other biomarkers less used are: Serum
alpha amylase level, lipocalin-type prostaglandin D synthase, cysteinyl leukotrienes, and urinary
8-isoprostane [85–89]. Although the results seem promising, unfortunately these tests have shown an
unreliable specificity and sensitivity. In fact, chronic inflammation can be typical of patients affected by
OSAS (both adults and children) or may develop later on. Therefore, biomarkers cannot be used as
predictors. For this reason, they should be considered by physicians only as an integration of the data
coming from clinical evaluation and PSG.
Studies that have analyzed inflammatory factors and biomarkers as pediatric OSAS risk factor
have been reported in Table 6.
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Table 6. Studies that have analyzed inflammatory factors and biomarkers as pediatric OSAS risk factors.
Study Year Type of Study Patientsn◦ Age Parameters Evaluated Conclusions
Gozal D.
et al. [59] 2007
Prospective
study 355 5–7
AHI, RDI, SaO2; Positive correlation
between APOE epsilon4
allele and OSA and
neurocognitive deficits
Neurocognitive tests;
Blood draw.
Khalyfa A.
et al. [60] 2011
Case–control
study 140 <6
ESS questionnaire; Positive correlation
between high TNF- α levels
and OSAS
AHI, RDI, SaO2M;
Serum TNF- α
Tam C.S.
et al. [79] 2006
Case–control
study 113 7.3 ± 3.7
C-reactive protein; Significantly elevated
IFN-gamma levels and
elevated IL-8 levels
Cytokines: IL-1beta,
IL-2, IL-4, IL-6, IL-8,
IL-10, IL-12, GM-CSF,
IFN-gamma and
TNF-alpha.
Gozal et al.
[80] 2008
Case–control
study 40 6.5 ± 0.7
Age and sex;
Higher levels of IL-6 and
IL-10
Ethnicity;
BMI:
AHI, RDI;
IL-6, IL-10.
Park C.S.
et al. [85] 2014
Case–control
study 67 6 (3–16)
Age and sex; High level of serum alpha
amilase in severe OSAS
children compared to
moderate and mild ones
and to the control group
BMI;
AHI, RDI;
OSA-18 questionnaire;
Alpha amilase levels.
Gozal D.
et al. [86] 2009
Case–control
study 60 6.6 ± 0.7
Clinical questionnaires; Consistent alterations in
urinary concentrations of
specific protein clusters in
OSA patients
Height and weight;
BMI;
AHI; RDI, SaO2;
Urine collection
3. Clinical Presentation
The clinical presentation of a child with OSAS is quite suggestive and can be divided into physical
findings and symptoms. At general examination, these patients present obesity, long face syndrome,
craniofacial alterations, and elevated systemic blood pressure. Moreover, the ENT physical examination
may frequently show adeno-tonsillar hypertrophy, inflammation of the nasal mucosa, deviation of the
nasal septum, hypertrophy of the inferior turbinates, ogival palate, or macroglossia. [90,91].
The symptoms are classically divided into nocturnal and diurnal. Among the latter, the most
frequent are daytime sleepiness, recurrent headache, nasal speech, hyperactivity, inattention, depression,
mood instability, irritability, and aggressiveness [92,93].
Nocturnal symptoms include snoring, witnessed apnea, oral breathing, paradoxical thoracic
movements, nightmares, sleepwalking, and nocturnal enuresis [94]. The well-known long-term
complications in the adult population should also be mentioned, because they may also occur in the
OSA pediatric population. In fact, several studies have shown an increased risk of cardiovascular
and pulmonary complications, such as pulmonary hypertension, or pulmonale and right heart failure.
Indeed, high levels of CRP, brain natriuretic peptide, adhesion molecules, myeloid-related protein 8/14,
fatty acid-binding protein, and other factors resulting from vascular injury and endothelial activation
have all been demonstrated in children with OSAS [95,96].
Moreover, children affected by severe OSAS may develop an early metabolic syndrome. This
critical condition is characterized by a cluster of pathologies: Obesity, insulin resistance, systemic
hypertension, and dyslipidemia. Although the association is still not clear, several studies have
highlighted the link between sleep fragmentation and intermittent hypoxia in obese children and
down-regulated insulin sensitivity [97–101].
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4. Diagnosis
The diagnosis of pediatric OSAS is a process composed of several steps. In children the clinical
presentation is more nuanced and therefore simple clinical evaluation is often misleading. The clinical
history of patients with suspected OSAS is reconstructed by administering specific questionnaires
to their parents. The role of the questionnaires and their effectiveness in the diagnostic process are
currently under study. In particular, of all those developed, six are the most interesting and most
frequently used in clinical practice.
The Pediatric Sleep Questionnaire (PSQ) is the most widely used survey consisting of 22
close-ended questions.
The current guidelines of the European Respiratory Society Task Force define PSQ as a good test
for identifying children affected by OSAS with an apnea-hypopnea index (AHI) > 5 [102].
Other less frequently used questionnaires are: Sleep clinical record (SCR) [103], OSA-18 [104], the
Broullette score (BS), and I’M SLEEPY [105].
The latest and newest one is the Sleeping Sleepless Sleepy Disturbed Rest questionnaire (SSSDR).
Presented in Rome in 2018, it is not included in the latest guidelines but seems to be very promising [106].
The work of Burghard et al. [107] has summed up these questionnaires. Although very useful, they
still need more studies in order to be improved or to further diagnostic steps. Following the assessment
of the medical history and questionnaires, the general and ENT examination is of primary importance.
The general physical examination evaluates the following parameters: Height and weight growth,
neuro-behavioral factors, cardiological and pneumological conditions, and eventual co-morbidities.
Therefore, the collaboration between several specialists appears to be fundamental. The ENT physical
examination includes an accurate assessment of the upper airway. Adenoid hypertrophy is assessed
by nasal endoscopy. There are conflicting opinions on what the role of isolated adenoid hypertrophy
in the genesis of OSAS may be. In fact, many studies show that adenoid hypertrophy is not sufficient
to determine OSAS, but it can worsen its severity in children with other risk factors [108]. As already
mentioned, tonsillar hypertrophy is one of the most frequent causes of OSAS in otherwise healthy
children and there is also a correlation between tonsillar grade and OSAS severity [109].
However, not all children with marked tonsillar hypertrophy are affected by OSAS. Thus, there
is an individual variability regarding the upper airway muscle tone. Particularly in obese children
and in those suffering from neuromuscular diseases, tonsillar hypertrophy does not play a significant
role [110].
The presence of dento-facial anomalies also belongs to the typical presentation of an OSA child.
For this reason, the ENT specialist should also involve the orthodontist who, by assessing the extra
and intra-oral morphological characteristics, can select patients suitable for conservative treatment.
However, recent studies have shown that the adenotonsillectomy is capable of restoring correct
maxillo-mandibular morphology, thus supporting the thesis that dento-facial skeletal anomalies are
more a consequence of OSA than the cause [111].
Nocturnal oximetry is the most widely used screening technique for children with a strong clinical
suspicion of pediatric OSAS. In fact, it has a low cost and is easy to carry out and interpret. Although
its positivity permits the diagnosis of OSAS, its negativity does not exclude the pathology. According
to Kirk et al. [112], the sensitivity and specificity of oximetry for the identification of moderate OSAS
(AHI > 5/h), compared to the laboratory PSG test, were 67% and 60%, respectively. These authors also
noticed that the oximetry algorhythm tended to overestimate the ODI at low levels and underestimate
at high levels. For that reason, oximetry alone was not adequate for the diagnosis of OSAS.
Ambulatory polysomnography is the monitoring of cardiorespiratory features during sleep
performed at the patient’s home. Despite the high sensitivity and specificity of the examination
carried out on adult patients, its effectiveness in children is strongly related to their age. In fact,
although there are several studies which validate its efficacy in school-aged children, there are a few
discrepancies in the data regarding younger children [113]. Zucconi et al. [114] proposed a home
portable system comprising measurements of airflow, snoring, chest and abdominal wall movements,
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electrocardiography (ECG), position, and oximetry. They used it in the sleep laboratory for the study.
A small sample of 12 children, 3 to 6 years of age, underwent routine PSG and in-laboratory portable
testing on consecutive nights using the portable system. The outcome showed a good sensitivity for
detecting a respiratory distress index, but a poor specificity. Nocturnal laboratory polysomnography is
considered the gold standard in children in whom there is a high suspicion of OSAS. It is performed
monitoring modifications in the electroencephalogram during sleep as well as cardiorespiratory
function, airflow, and nocturnal oximetry. It is indicated for quantifying the severity of the disease,
for preoperative evaluation, for predicting post-operative complications and the persistence of sleep
breathing disorders after treatment. An important aspect is that the compliance to this exam is different
in children and in adults. In fact, there is an anxious component in adults that does not allow adequate
sleep. The same does not occur in children. This is well explained in several studies which have
evaluated the so-called night-to-night variability, and ended up with the result that, in children,
one night PSG is adequate. [115–118].
There is another test used in children: Nap PSG. It records sleeping and breathing in laboratory
conditions during daytime. It is a simple and reliable test with a high sensibility and specificity [119].
Drug-induced sleep endoscopy (DISE) is mainly used in the pediatric population for the correct
approach to children with residual OSAS after surgery. The main goal is to analyze the type of
obstruction at the anatomical site of potential collapse [120].
The anesthetic protocol represents a debated point. Inhalation therapy with halothane or
sevoflurane was used at the beginning, but several alterations to the pharyngeal muscle tone have
led to it being progressively substituted by intravenous drugs, such as propofol, ketamine with
glycopyrrolate, remifentanil, and midazolam [120].
Chen et al. [121] evaluated the role of DISE in the diagnosis and consequent aimed treatment in
children with small tonsils. Their conclusion was that DISE is also required to evaluate the necessity
of combined adenotonsillectomy in patients with a finding of small tonsils at clinical examinations.
They focused on the differences between awake endoscopy and DISE. The main one is the possible
underestimation of collapse in wakefulness. Moreover, the oropharynx obstruction was better defined
in DISE than in awake endoscopy.
In conclusion, although DISE has a well-defined codification in adults, the same cannot be said
for children. This could be considered a paradox considering that the first study published in the
literature regarding sleep endoscopy was the one by Croft in 1990 in a pediatric population [122].
5. Conclusions
Obstructive sleep apnea in children is a condition with a multi-factorial etiology. The study of
each single risk factor and of the associated comorbidities as well as the continuous monitoring of the
patients are therefore of fundamental importance in order to be able to plan and eventually modify the
therapeutic process correctly.
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AASM American Association Sleep Medicine
AHI Apnea-Hypopnea index
AT Adenotonsillectomy
AR Allergic Rhinitis
BMI Body Mass Index
CPAP Continuous Positive Airway Pressure
CRP Reactive C- Protein
DISE Drug Induced Sleep Endoscopy
ERS European Respiratory Society
ESS Epworth Sleepiness Scale
ICSD-3 International Classification of Sleep Disorders
ODI Oxygen Desaturation Index
OSA Obstructive sleep apnea
OSAS Obstructive sleep apnea syndrome
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RDI Respiratory Disease Index
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